OssDsign to Collect Data on Catalyst Bone Graft

OssDsign received review board approval to establish PROPEL, a multi-center prospective spinal fusion registry, to study real-world data from patients who have been treated with OssDsign Catalyst.

OssDsign Catalyst received FDA clearance in 2020 and was launched in the U.S. in 2021. During 2022, clinics will gradually be enrolled to the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us